Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Biochemia Medica|February 18, 2020
Analytical verification and comparison of chromogenic assays for dabigatran, rivaroxaban and apixaban determination on BCSXP and STA Compact Max analysersIvana Ćelap, Sandra Margetić, Marija Brčić, et al.
Biochemia Medica|April 11, 2017
Policies and practices in haemostasis testing among laboratories in Croatia: a survey on behalf of a Working Group for Laboratory Coagulation of the Croatian Society of Medical Biochemistry and Laboratory MedicineAna Bronić, Desiree Coen Herak, Sandra Margetić, et al.
Biochemia Medica|June 22, 2019
Croatian Society of Medical Biochemistry and Laboratory Medicine: National recommendations for blood collection, processing, performance and reporting of results for coagulation screening assays prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen and D-dimerAna Bronić, Desiree Coen Herak, Sandra Margetić, et al.
Acta Pharmaceutica (Zagreb, Croatia)|January 18, 2023
Direct oral anticoagulants (DOACs): From the laboratory point of viewSandra Margetić, Sandra Šupraha Goreta, Ivana Ćelap, et al.
Biochemia Medica|June 28, 2016
Interference of M-protein on prothrombin time test - case reportSandra Margetić, Ivana Ćelap, Lora Dukić, et al.
Croatian Medical Journal|November 3, 2022
Lupus anticoagulant-hypoprothrombinemia syndrome with severe bleeding diathesis after coronavirus disease 2019: a case reportTomislav Brblić, Klara Brčić, Sandra Margetić, et al.
Biochemia Medica|October 22, 2024
CCL20 chemokine and other proinflammatory markers after Ad26.COV2.S vaccinationIva Ivanko, Milena Hanžek, Ivana Ćelap, et al.
Biochemia Medica|June 18, 2021
Reporting of activated partial thromboplastin time (aPTT): Could we achieve better comparability of the results?Ana Bronić, Sandra Margetić, Desiree Coen Herak, et al.
Laboratory Medicine|February 14, 2020
Interference of M-protein on Thrombin Time Test: A Case ReportMilena Njegovan, Sandra Margetić, Andrea Tešija Kuna, et al.
Biochemia Medica|December 17, 2019
Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitationsSandra Margetić, Ivana Ćelap, Diana Delić Brkljačić, et al.
Pageof 2